Cytochrome P450

Pulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled Opelconazole

Retrieved on: 
星期一, 十月 16, 2023
ID, Cytochrome P450, Midazolam, Chronic pulmonary aspergillosis, Antifungal, Risk, Inhalation, Disease, Drug, Clinical trial, Bronchospasm, Caffeine, CYP1A2, Patient, CYP3A4, Pharmaceutical industry

The results from these in vitro studies subsequently informed the design of a Phase 1 drug-drug interaction study in 24 healthy volunteers.

Key Points: 
  • The results from these in vitro studies subsequently informed the design of a Phase 1 drug-drug interaction study in 24 healthy volunteers.
  • “Opelconazole was specifically designed to be administered via inhalation in order to achieve high lung concentrations and low systemic uptake.
  • These low systemic levels, now observed in multiple clinical trials and in the UK Special Needs provision, have been estimated to be too low to have an inhibition or induction of a drug-drug interaction effect.
  • We are encouraged that these clinical trial results confirm this low potential for Cytochrome P450 drug-drug interactions for opelconazole.”

PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

Retrieved on: 
星期三, 三月 16, 2022
Oncology, Health, Diabetes, Genetics, Pharmaceutical, Biotechnology, HEK293, U.S. Securities and Exchange Commission, Program, Technology, Cell, Ifosfamide, FDIC, Private Securities Litigation Reform Act, Capsule, FDA, Form, Cytochrome, Cytochrome P450, Diabetes, Immortalised cell line, NASDAQ, Neoplasm, IND, Form 10-K, Clinical trial, Insulin, Pancreatic cancer, Food, Liver, Company, Research, Cancer, Ascites, Biotechnology, R, Catheter, Vii, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LAPC, PMCB, Pharmaceutical industry, Online gambling, Medical device, Medical imaging

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today the financial and operational results for its third quarter ended January 31, 2022, and provided an overview of recent operational highlights (PharmaCytes Fiscal Year begins May 1 and ends April 30).

Key Points: 
  • PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today the financial and operational results for its third quarter ended January 31, 2022, and provided an overview of recent operational highlights (PharmaCytes Fiscal Year begins May 1 and ends April 30).
  • Cash Position: PharmaCyte had approximately $87 million in cash on hand as of January 31, 2022.
  • In November 2021, PharmaCyte announced that the empty capsule material that makes up its CypCaps pancreatic cancer product does not cause skin irritation.
  • In December 2021, PharmaCyte successfully completed the 36-month time point in its ongoing Master Cell Bank stability study.

Nephraegis Therapeutics Launches with Seed Financing to Develop Small Molecules to Prevent and Treat Acute Kidney Injury (AKI)

Retrieved on: 
星期三, 五月 12, 2021
Biotechnology, FDA, Managed care, Other Health, Health, Radiology, Pharmaceutical, Other Science, Research, Science, Clinical trials, Branches of biology, Animal physiology, Cell biology, Human physiology, Metabolic pathways, Cytochrome P450, Epoxyeicosatrienoic acid, Acute kidney injury, Aki, Kidney, NPH-022, Nephraegis Therapeutics, Inc., Xontogeny, LLC, NPH-022, NEPHRAEGIS THERAPEUTICS, INC., XONTOGENY, LLC

b"Nephraegis Therapeutics, Inc., a biopharmaceutical company developing NPH-022 to prevent and treat Acute Kidney Injury (AKI) today announced their launch with a seed investment from Xontogeny, LLC to advance their lead compound through critical preclinical work.\nThis press release features multimedia.

Key Points: 
  • b"Nephraegis Therapeutics, Inc., a biopharmaceutical company developing NPH-022 to prevent and treat Acute Kidney Injury (AKI) today announced their launch with a seed investment from Xontogeny, LLC to advance their lead compound through critical preclinical work.\nThis press release features multimedia.
  • Nephraegis' lead compound, NPH\xe2\x80\x91022, acts via the same pathway as endogenous epoxyeicosatrienoic acids (EETs), which regulate normal kidney function to respond to cellular stress events such as hypoxia or chemotoxicity.
  • This is especially important for our initial target, developing NPH-022 as a potentially promising new treatment to prevent AKI.\xe2\x80\x9d\nAKI is an abrupt loss of kidney function.
  • Nephraegis Therapeutics undertakes no obligation to update any forward-looking statements for any reason.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005296/en/\n"

PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for its Clinical Trial Product

Retrieved on: 
星期二, 一月 26, 2021
Biotechnology, Pharmaceutical, Oncology, Health, FDA, Diabetes, Genetics, Clinical trials, Metabolism, Integral membrane proteins, Pharmacokinetics, Branches of biology, Cytochrome P450, Biochemistry, Biology, Cytochrome P450 reductase, CYP4F22

The cell clone used to produce the CypCaps product has been augmented to produce the cytochrome P450 enzyme.

Key Points: 
  • The cell clone used to produce the CypCaps product has been augmented to produce the cytochrome P450 enzyme.
  • The FDA has now asked PharmaCyte to provide the exact DNA sequence and configuration of the genetic augmentation responsible for the production of cytochrome P450 in the cells.
  • This requires additional studies that necessitates a multi-prong approach, including the employment of a new, state of the art, technique.
  • Thus, these new studies will add to the data that PharmaCyte already has on the long-term stability and shelf life of the final CypCaps product.

Agena Improves PGx Testing Accuracy with Launch of VeriDose™ CYP2D6 CNV Panel to Detect Hybrid Alleles

Retrieved on: 
星期一, 十一月 4, 2019
Amphetamine, CYP2D6, Cytochrome P450, Branches of biology, Genomics, Copy-number variation

SAN DIEGO, Nov. 4, 2019 /PRNewswire/ --Agena Bioscience, a global provider of molecular testing solutions, today announced the release of the VeriDose CYP2D6 CNV panel designed to provide PGx testing programs with a more accurate and efficient way to analyze CYP2D6 copy number.

Key Points: 
  • SAN DIEGO, Nov. 4, 2019 /PRNewswire/ --Agena Bioscience, a global provider of molecular testing solutions, today announced the release of the VeriDose CYP2D6 CNV panel designed to provide PGx testing programs with a more accurate and efficient way to analyze CYP2D6 copy number.
  • The RUO panel quantifies CYP2D6 copy number, even in the presence of CYP2D6/CYP2D7 hybrid alleles which cannot be detected by commonly used PGx technologies.
  • "Depending on ethnicity, up to 37% of individuals possess a CYP2D6/CYP2D7 hybrid allele," said Houda Hachad, Pharm.D, Chief Scientific Officer at Translational Software.
  • We are excited to support Agena's new VeriDose CYP2D6 CNV panel which will help our customers produce more reliable results."

OneOme Expands its Comprehensive Pharmacogenomic Test Offering with New Genes and Medications

Retrieved on: 
星期二, 五月 22, 2018
Genomics, Pharmacology, Pharmacy, Methylenetetrahydrofolate reductase, Cytochrome P450, Pharmacogenomics, Health, CYP2C19, DPYD, UDP glucuronosyltransferase 1 family, polypeptide A1, Biology

In addition to these updates, OneOme now gives providers the option to order the MTHFR gene as a complimentary add-on to the RightMed test.

Key Points: 
  • In addition to these updates, OneOme now gives providers the option to order the MTHFR gene as a complimentary add-on to the RightMed test.
  • "With these enhancements to our product, OneOme is continuing to make progress toward providing the highest quality, most cost-effective and clinically relevant pharmacogenomic solution for patients and providers across the globe," said Paul Owen, CEO of OneOme.
  • "Adding HLAs to our comprehensive panel has been a goal since the very beginning," said Ross Higgins, director of laboratory operations and clinical development at OneOme.
  • In addition to updates to its RightMed product, OneOme now offers single gene tests for DPYD, UGT1A1, CYP2C19, and MTHFR.